| 抗HER-2靶向治疗乳腺癌在研临床试验进展 |
| |
| 引用本文： | 佟仲生. 抗HER-2靶向治疗乳腺癌在研临床试验进展[J]. 中国肿瘤临床, 2017, 44(13): 630-634. DOI: 10.3969/j.issn.1000-8179.2017.13.115 |
| |
| 作者姓名： | 佟仲生 |
| |
| 作者单位： | 天津医科大学肿瘤医院乳腺肿瘤内科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，乳腺癌防治教育部重点实验室（天津市 300060） |
| |
| 基金项目： | The National Science and Technology Pillar Program (No. 2015BAI12B15)本文课题受国家科技支撑计划项目(2015BAI12B15) |
| |
| 摘 要： | 目前抗人表皮生长因子受体2（human epidermal growth factor receptor-2，HER-2）阳性乳腺癌临床研究关注不同机制下靶向药物的联合、靶向药物与内分泌治疗联合、双靶向药物与化疗药物联合，目的是为未来抗HER-2临床治疗指明方向。本文着重介绍国内外在研的Ⅱ~Ⅲ期临床试验，同时介绍有较好应用潜能的靶向药物，主要包括新型小分子靶向药物、单克隆抗体靶向药物、单克隆抗体偶联物、双靶点药物联合治疗、靶向药物联合内分泌治疗、靶向联合化疗、曲妥珠单抗皮下注射制剂、HER-2肿瘤疫苗等。
|
| 关 键 词： | 乳腺癌 靶向治疗 HER-2 |
| 收稿时间： | 2017-02-03 |
Clinical research progress on treatments for HER-2-positive breast cancer |
| |
| Affiliation: | Internal Medicine Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China |
| |
| Abstract: | For HER-2 positive breast cancer, HER-2-targeted agents combined with agents that target downstream signaling or alternative pathways, and endocrine therapy has been investigated in clinical settings. This paper focuses on studies involving phaseⅡand phaseⅢclinical trials for new targets with enhanced clinical applications, including novel small molecular targeting agents, monoclonal antibody-targeted drugs, monoclonal antibody conjugates, dual target drug combination therapy, drug targeting combined with endocrine and targeted chemotherapies, trastuzumab subcutaneous injection, and HER-2 tumor vaccine. |
| |
| Keywords: | breast cancer targeted therapy human epidermal growth factor receptor-2 |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
